Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

HK - Action in Anta, China Gas, Sunny Optical, Ascletis Pharma, Sa Sa, CMS

Ascletis Pharma: Reiterate Sell, 29% Downside

HK - Shorts Pile Into Tencent, CCB, Ping An, Sunny Optical, AIA; Cover Mobile, China Tower, BYD

Ascletis Pharma (歌礼制药) Post-Listing: Thoughts on Liquidity and Bull Cases

Ascletis Pharma (歌礼制药) IPO: Valuation Not Justified by Ganovo and Ravidasvir NPV (Part 3)

Ascletis Pharma (歌礼制药) IPO: Three Valuation Risk Factors (Part 2)

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Event-Driven

<p>Ascletis Pharma has been the beneficiary of the Coronavirus as media reports mention that its drug candidates that aim to treat type 1 HIV is being used by hospitals to treat coronavirus. In this insight, we will analyse the possible outcome of the possible clinical trial and our view that recent outperformance is an overreaction, from valuation point of view. </p>

Ascletis Pharma has been the beneficiary of the Coronavirus as media reports mention that its drug candidates that aim to treat type 1 HIV is being used by hospitals to treat coronavirus. In this insight, we will analyse the possible outcome of the possible clinical trial and our view that recent outperformance is an overreaction, from valuation point of view. 

Ascletis Pharma: Sell the Hype Of (Possible) Coronavirus Clinical Trial

Ascletis Pharma Inc

Ascletis Pharma: Sell the Hype Of (Possible) Coronavirus Clinical Trial